New cell therapy tested for severe lupus patients
NCT ID NCT06530849
Summary
This early-stage study is testing an experimental injection called GC012F in adults with severe systemic lupus erythematosus (lupus) that hasn't improved with standard treatments. The main goals are to check if the treatment is safe and to find the right dose. Researchers will also look for signs that it helps control lupus disease activity over 48 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGShanghai, China
-
Research Site
RECRUITINGWuhan, 430060, China
Conditions
Explore the condition pages connected to this study.